Amarantus BioScience Holdings, Inc. “Q1-2014: The Maturation of Amarantus”

Publishing & Media

Share Tweet

Amarantus BioScience Holdings, Inc. “Q1-2014: The Maturation of Amarantus”

Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) published a new blog post on The Chairman’s Blog, written by the company’s CEO, Gerald Commissiong. is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.

Amarantus CEO, Gerald Commissiong writes about the implications of being a small company in the biotech industry. He highlights the recent progress Amarantus has made, with additions to the management team and the expansion of the Company’s pipeline. Mr. Commissiong writes, “For Amarantus, we have taken the view that building a world-class biotechnology company in the absence of product revenue (for the time being) requires a number of key elements in order to truly thrive.” Read about those key elements in his blog post on (

About Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.